Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib for BTK inhibitor-intolerant CLL/SLL
ChiCTR2300071096Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of orelabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Ruijin Hospital. Primary endpoint: adverse events. Planned start May 2023; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2300071096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071096.